Idexx Laboratories Inc (IDXX)

About Idexx Laboratories Inc

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.

Latest reported results

IDEXX Laboratories, Inc. reported revenue of $1.22 billion for Q2 FY2026, up 9.7% from the same period a year earlier.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 1,269 institutions reported holding IDXX, with 73.1 million shares worth $38.5 billion in aggregate. The largest reported holders were Vanguard, BlackRock and State Street. Of the 5 largest reported holders, 2 added shares and 3 reduced their positions during the quarter.

More on IDXX

• IDXX sentiment: whether news and social coverage of Idexx Laboratories Inc leans bullish or bearish, and the stories driving it.
• IDXX ownership: all 1,269 reporting institutions, plus insider and congressional trades.
• IDXX financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.

SentiSense also tracks daily options readings for Idexx Laboratories Inc: IV rank, put/call percentile, 25-delta skew and open-interest walls.

Frequently asked questions